Literature DB >> 8380528

Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations.

L S Forno1, L E DeLanney, I Irwin, J W Langston.   

Abstract

The MPTP monkey model for PD has continued to display similarities as well as differences from the human disease, also in respect to its neuropathology. In 65 MPTP-treated squirrel monkeys with survival for more than 2 days, the main similarities consisted of nerve cell degeneration, not only of SN, but also, in the majority of cases, of the LC. In 13 animals that survived for from 1 to 7 years after their first exposure to MPTP, the nerve cells in the ventrolateral portion of the SN compacta were particularly vulnerable, just as in PD. The principal differences were the lack of progression of the disease process in these long-term animals (although this has yet to be systematically tested) and the absence of formation of typical Lewy bodies in the SN, LC, and other predilection sites for Lewy bodies. Since inclusion bodies, now observed in 16 monkeys, could be produced fairly consistently in aged MPTP-treated squirrel monkeys, they appeared to represent a bridge between these similarities and differences. They had some features, especially their location in predilection sites for Lewy bodies, such as the SN, in common with Lewy bodies, but did not display the fully convincing morphological and immunocytochemical features, characteristics of the human inclusion bodies in PD. Overall, these studies continue to provide tantalizing hints that this model could lead to important new insights into the pathologic process that underlies PD.

Entities:  

Mesh:

Year:  1993        PMID: 8380528

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  57 in total

1.  Sonic hedgehog promotes the survival of specific CNS neuron populations and protects these cells from toxic insult In vitro.

Authors:  N Miao; M Wang; J A Ott; J S D'Alessandro; T M Woolf; D A Bumcrot; N K Mahanthappa; K Pang
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

Review 2.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

3.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Authors:  Francesco Fornai; Oliver M Schlüter; Paola Lenzi; Marco Gesi; Riccardo Ruffoli; Michela Ferrucci; Gloria Lazzeri; Carla L Busceti; Fabrizio Pontarelli; Giuseppe Battaglia; Antonio Pellegrini; Ferdinando Nicoletti; Stefano Ruggieri; Antonio Paparelli; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

Review 4.  Pathophysiology of parkinsonism.

Authors:  Adriana Galvan; Thomas Wichmann
Journal:  Clin Neurophysiol       Date:  2008-05-07       Impact factor: 3.708

Review 5.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 7.  Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?

Authors:  Christopher A Shaw; Günter U Höglinger
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

8.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

Authors:  S Przedborski; V Jackson-Lewis; R Yokoyama; T Shibata; V L Dawson; T M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

9.  Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

Authors:  William Lin; Un Jung Kang
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

10.  Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders.

Authors:  G M Murphy; L S Forno; L Higgins; J M Scardina; L F Eng; B Cordell
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.